1987 Volume 15 Issue 3 Pages 611-617
The present study was undertaken to elucidate the effect of combined therapy with clinofibrate and melinamide on serum lipid. Thirteen patients with type ha hyperlipidemia were divided into two groups. Six patients were given clinofibrate and seven patients were given melinamide for first 12 weeks. And then all patients were given both clinofibrate and melinamide for additional 24 weeks. Blood samples were collected at 12 hours fasting in order to measure cholesterol (ch.) and triglyceride (TG) in whole serum and lipoprotein fractions (VLDL, LDL, HDL, HDL2 and HDL3) and apolipoprotein (A-I, A-II, B, C-II, C-III and E) before therapy and at every 12 weeks.
The results obtained were as follows:
(1) Only total ch. decreased significantly with single therapy of both clinofibrate and melinamide. With combined therapy the significant decrease in VLDL ch., LDL ch. and total TG level were recognized. HDL ch. also decreased significantly associated with HDL2 ch. subfraction level.
(2) In apolipoprotein profile, clinofibrate decreased apo A-I and melinamide increased apo E significantly with each single therapy, respectively. Apo A-I, A-II and C-III decreased significantly with combined therapy.
(3) Atherogenic index (HDL ch./LDL ch. ratio) did not change in all period, but the differences between LDL ch. and HDL ch. (LDL ch.—HDL ch.) was decreased significantly with combined therapy. We concluded that combined therapy decreased not only the atherogenic lipoproteins, but also the antiatherogenic lipoproteins. So further investigation is necessary to clarify whether combined therapy is effective on hyperlipidemia and atherogenic index is an adequate parameter on purpose to evaluate antihyperlipidemic drug effect.
